Fesoterodine

Chemical compound

EU EMA: by INN
US DailyMed: Fesoterodine
US FDA: Fesoterodine

Routes of
administrationBy mouthATC code

G04BD11 (WHO)

CA: ℞-only
US: ℞-only
EU: Rx-only

Pharmacokinetic dataBioavailability52% (active metabolite)Protein binding50% (active metabolite)MetabolismLiver (CYP2D6- and 3A4-mediated)Elimination half-life7–8 hours (active metabolite)ExcretionKidney (70%) and fecal (7%)Identifiers

IUPAC name

[2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate

CAS Number

286930-02-7^N

PubChem CID

6918558

IUPHAR/BPS

7473

DrugBank

DB06702^Y

ChemSpider

5293755^Y

UNII

621G617227

KEGG

D07226^Y

ChEMBL

ChEMBL1201764^N

CompTox Dashboard (EPA)

DTXSID80182853

ECHA InfoCard100.184.854

Chemical and physical dataFormulaC₂₆H₃₇NO₃Molar mass411.586 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

O=C(Oc1ccc(cc1[C@@H](c2ccccc2)CCN(C(C)C)C(C)C)CO)C(C)C

InChI

InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1^Y
Key:DCCSDBARQIPTGU-HSZRJFAPSA-N^Y

^NY (what is this?) (verify)

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).^[2] It was approved by the European Medicines Agency in April 2007,^[3] the US Food and Drug Administration on October 31, 2008 ^[4] and Health Canada on February 9, 2012.^[5]

Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.

Efficacy

Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.^[6] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.^[6]

A Japanese study from 2017, showed that urgency and urge incontinence are improved after 3 days administration of the drug, with full efficacy able to be judged after 7 days administration. Overactive bladder was found to be resolved in 88% of patients after seven days usage. ^[7]

References

^ "Fesoterodine (Toviaz) Use During Pregnancy". Drugs.com. 7 November 2019. Archived from the original on 29 November 2020. Retrieved 12 August 2020.
^ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. Archived from the original on 16 May 2011. Retrieved 2 November 2007.
^ "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008. Archived from the original on 2008-04-01.
^ "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Archived from the original on 2018-09-20. Retrieved 2008-11-06.
^ "Notice of Decision for TOVIAZ". Archived from the original on 2012-04-23. Retrieved 2012-04-20.
^ ^a ^b Vella M, Cardozo L (September 2011). "Review of fesoterodine". Expert Opinion on Drug Safety. 10 (5): 805–8. doi:10.1517/14740338.2011.591377. PMID 21639817. S2CID 9653506.
^ "Sato N, Fuji K, Ogawa Y (2017). "Transactions of The Showa University Society: The 335th Meeting". The Showa University Journal of Medical Sciences. 29 (2): 201–217. doi:10.15369/sujms.29.201. ISSN 2185-0968.